Skip to Main Content
Contribute Try STAT+ Today

In a surprise move, Maryland Gov. Larry Hogan vetoed state funding for a “Prescription Drug Affordability Board,” which was created last year to establish maximum prices that the state and local governments will pay for “high-cost” medicines.

The entity is designed to function like rate-setting boards that regulate what public utilities can charge residents. The board emerged last year after the U.S. Supreme Court scuttled a state law that aimed to bar drug makers from “price gouging” consumers. The pharmaceutical industry opposed its creation by arguing it was a form of price controls and, ultimately, would have limited choices for state residents.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.